Cargando…

P1192: ANTI-PD-1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R-CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B-CELL LYMPHOMA: A PROSPENTIVE PHASE II STUDY

Detalles Bibliográficos
Autores principales:	Mei, Wu, Lin, Zhu, Shan, LI, Erbao, Tu Erde Jia, Shanshan, Wang, Xiao, Liang, Xin, Hu, LI, Guo, Dili Abulikemujiang, A, Xianmusiya, Maimaitirexiati, Ruirui, Ren, Shujuan, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431144/ http://dx.doi.org/10.1097/01.HS9.0000971664.08620.74

Ejemplares similares

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer
por: Lu, Shun, et al.
Publicado: (2022)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2021)

MJRA1.19.2 - Integrated EMI Major Release Candidates
por: Members of EMI collaboration
Publicado: (Febr)

Correction to Lancet Glob Health 2017; 5: e1192–207
Publicado: (2017)

1192. Validation of an Electronic Dashboard in Identifying Excess Duration of Antibiotics for Pneumonia
por: Ferranti, Mary, et al.
Publicado: (2023)

Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy
por: Xu, Xiao-xiao, et al.
Publicado: (2013)

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
por: Gleeson, Mary, et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma
por: Samineni, Divya, et al.
Publicado: (2021)

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL
por: Song, Y., et al.
Publicado: (2022)

Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review
por: Yang, Hujuan, et al.
Publicado: (2023)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
por: Hong, Yuan, et al.
Publicado: (2021)

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
por: Gong, Jinhong, et al.
Publicado: (2022)

Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
por: Xu, Li, et al.
Publicado: (2021)

Secular trends in 1,192 diarrheal outbreaks in the Israel Defence Forces between 1988–2011
por: Elazar, Sharon, et al.
Publicado: (2015)

1192. H-NS-like Proteins in Pseudomonas aeruginosa Coordinately Silence Intragenic and Antisense Transcription
por: Lippa, Andrew M, et al.
Publicado: (2020)

EP1192: LIVER TEST ABNORMALITIES IN COVID-19 PATIENTS MAY NOT BE RELATED TO CYTOKINE STORM
por: Piskorz, Maria, et al.
Publicado: (2022)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
por: Sehn, Laurie H., et al.
Publicado: (2020)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020)

Short-term Clinical Outcome of Previously Untreated and Treated Schizophrenia and Impact of Duration of Untreated Psychosis
por: Bansal, Priyanka, et al.
Publicado: (2023)

Previously treated versus untreated scoliosis: are results different?
por: Zaina, Fabio, et al.
Publicado: (2014)

HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA
por: Dormoy-Raclet, Virginie, et al.
Publicado: (2013)

1192. Identification of a Novel Enterobacter cloacae Isolate Producing an IMP-13 Metallo-β-Lactamase
por: Abid, Muhammad Bilal, et al.
Publicado: (2018)

Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
por: Nemoto, Kenji, et al.
Publicado: (2002)

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
por: Lisenko, K., et al.
Publicado: (2017)

Complete Genome Sequence of Mesorhizobium ciceri Strain CC1192, an Efficient Nitrogen-Fixing Microsymbiont of Cicer arietinum
por: Haskett, Timothy, et al.
Publicado: (2016)

Cost-effective sequence analysis of 113 genes in 1,192 probands with retinitis pigmentosa and Leber congenital amaurosis
por: Panneman, Daan M., et al.
Publicado: (2023)

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
por: Lu, Zhihao, et al.
Publicado: (2022)

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
por: Zhu, Wenyu, et al.
Publicado: (2022)

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
por: Ren, Zhenggang, et al.
Publicado: (2022)

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results
por: Stefoni, V, et al.
Publicado: (2016)

P1171: REFLECT: PROSPECTIVE NON-INTERVENTIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF SANDOZ RITUXIMAB (SDZ-RTX) WITH CHOP FOR PATIENTS WITH PREVIOUSLY UNTREATED CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA
por: Welslau, M., et al.
Publicado: (2022)

Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma
por: Hwang, Shin, et al.
Publicado: (2022)

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
por: Held, Gerhard, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vrpalif44bgjaukljn38t7dq6n